Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
DPT0218 is a gut-restricted, highly potent and selective Kv1.3 inhibitor. It is being evaluated in preclinical studies for the treatment of Inflammatory Bowel Disease & Atopic Dermatitis.
Lead Product(s): DPT0218
Therapeutic Area: Gastroenterology Product Name: DPT0218
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2024